MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint ... MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.135 | 3.46153846154 | 3.9 | 4.245 | 3.81 | 578982 | 3.97804343 | CS |
| 4 | -0.485 | -10.7300884956 | 4.52 | 4.6401 | 3.81 | 654239 | 4.18046857 | CS |
| 12 | 1.255 | 45.1438848921 | 2.78 | 4.6401 | 2.73 | 988031 | 3.65310884 | CS |
| 26 | 2.685 | 198.888888889 | 1.35 | 4.6401 | 1.32 | 1159976 | 2.77734386 | CS |
| 52 | 2.555 | 172.635135135 | 1.48 | 4.6401 | 1.185 | 1055801 | 2.21574194 | CS |
| 156 | -2.045 | -33.6348684211 | 6.08 | 21.88 | 0.98965 | 1046646 | 5.26557049 | CS |
| 260 | -16.975 | -80.7948595907 | 21.01 | 29.16 | 0.98965 | 926771 | 6.56650891 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。